BUDGET PUSH TO MAKE INDIA A GLOBAL BIOPHARMA HUB

I have enough Tier 1 facts. Writing the note now.

BUDGET PUSH TO MAKE INDIA A GLOBAL BIOPHARMA HUB — UPSC Study Note

1. At a Glance

• Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) is a ₹10,000 crore, 5-year scheme announced in Union Budget 2026–27 to make India a global hub for biologics & biosimilars manufacturing [S1][S2].
• Bundled with NIPER expansion, 1,000+ accredited clinical trial sites, and CDSCO strengthening — a full-stack push covering R&D, talent, regulation, and manufacturing [S1][S3].
• Pharma is among 7 strategic & frontier sectors flagged for manufacturing scale-up in Budget 2026–27 [S1].

2. Why in the News

• Announced by FM Nirmala Sitharaman on 1 February 2026 in the Union Budget 2026–27 speech; the Department of Pharmaceuticals (Min. of Chemicals & Fertilizers) issued an official PIB explainer the same day [S1].
• Follow-on PIB releases (Feb 2026) by Dr. Jitendra Singh (MoS S&T) linked SHAKTI to India's biomanufacturing leadership ambitions [S2][S4].

3. Background & Evolution

• India is the "Pharmacy of the World" — 3rd largest by volume globally; bulk of output is generic small molecules, with weak presence in high-value biologics/biosimilars.
• Predecessor policy stack: PLI for Pharmaceuticals (2021), PLI for Bulk Drugs & Medical Devices, Bulk Drug Parks scheme, National Biopharma Mission (NBM, 2017) of DBT-BIRAC funded with World Bank support.
• NIPERs: Institutes of National Importance under the NIPER Act, 1998; flagship at NIPER Mohali (1998); SHAKTI adds 3 new + upgrades 7 existing [S2][S3].
• CDSCO: national drug regulator under DGHS, MoHFW — long flagged for capacity gaps in reviewing advanced therapies [S3].

4. Core Static Facts

• Scheme name: Biopharma SHAKTI — Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [S2].
• Outlay: ₹10,000 crore over 5 years from FY 2026–27 [S1][S2].
• Nodal Ministry: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S1].
• Regulatory partner: CDSCO (under MoHFW) — to get a dedicated Scientific Review Cadre incl. specialists for gene therapy [S2][S3].
• Clinical trial network: 1,000+ accredited sites under ICMR umbrella [S1][S3].
• NIPERs: 3 new + 7 upgraded (currently 7 NIPERs in India) [S1].
• Focus therapeutic areas: biologics & biosimilars for NCDs — cancer, diabetes, autoimmune disorders [S3].
• Frontier sectors basket: pharma is 1 of 7 strategic & frontier sectors in Budget 2026–27 [S1].

5. Multi-Dimensional Analysis

Economic - Targets the high-margin biologics segment, where global market is dominated by US/EU; import substitution + export earnings potential [S3]. - Skilled employment in R&D, clinical research, biomanufacturing; complements PLI-pharma [S2].

Scientific / Technological - Builds capacity in cell & gene therapy, biosimilars, AI-driven pharmacoinformatics, advanced drug delivery — areas flagged in NIPER Mohali's mandate under SHAKTI [S2]. - 1,000-site clinical trial network creates infrastructure for advanced/Phase-III trials locally [S3].

Administrative / Governance - Strengthening CDSCO with specialist reviewers addresses the chronic regulatory bottleneck for novel biologics approvals [S3]. - Multi-ministry coordination: DoP (scheme), MoHFW (CDSCO), ICMR (trials), DBT (biotech R&D) [S2][S3].

Geopolitical / Strategic - Reduces dependence on imported biologics; aligns with Atmanirbhar Bharat in critical health-tech. - Positions India as alternative to China in global biopharma supply chains [S2].

Social - Cheaper domestic biosimilars → improved affordability for cancer, diabetes, autoimmune patients [S3].

6. Recent Developments (last 12-18 months)

• 1 Feb 2026: SHAKTI announced in Budget 2026–27 speech [S1].
• Feb 2026: PIB explainer "Transforming India into a Global Biopharma Hub" released by DoP [S2].
• Feb 2026: MoS Dr. Jitendra Singh frames SHAKTI as catalyst for India's role in the "next industrial revolution" [S2].
• Post-Budget 2026: Union Health Minister J.P. Nadda visits NIPER Mohali, reviews biopharma research progress under SHAKTI [S2].

7. Prelims Hooks

• Biopharma SHAKTI full form: Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [S2].
• Outlay: ₹10,000 crore over 5 years [S1][S2].
• Announced in Union Budget 2026–27 (1 Feb 2026) [S1].
• Nodal: Department of Pharmaceuticals, Min. of Chemicals & Fertilizers (NOT MoHFW) [S1].
• 3 new NIPERs + 7 existing upgraded [S1].
• NIPER Act, 1998 — NIPERs are Institutes of National Importance.
• Clinical trial network: 1,000+ accredited sites under ICMR [S3].
• CDSCO to get a Scientific Review Cadre including gene therapy specialists [S2][S3].
• Pharma is one of 7 strategic & frontier sectors in Budget 2026–27 [S1].
• Focus: biologics & biosimilars targeting cancer, diabetes, autoimmune NCDs [S3].
• Predecessor scheme: National Biopharma Mission (2017) under DBT-BIRAC [reference].
• CDSCO is under DGHS, MoHFW, headed by DCGI.

8. Mains Relevance

• GS-III: Indian Economy — growth, industrial policy; Science & Tech — indigenisation, biotechnology; Health.
• GS-II: Government policies & interventions in health sector.
• Syllabus heading: "Issues relating to development & management of Social Sector — Health" and "Indigenisation of technology & developing new technology."
• Probable stems:
• "Critically examine the Biopharma SHAKTI scheme as a vehicle for moving India up the pharmaceutical value chain."
• "India is the pharmacy of the world in generics but a marginal player in biologics. Discuss the policy levers required to bridge this gap."
• "Regulatory capacity, not capital, is the binding constraint on Indian biopharma. Examine in light of recent CDSCO reforms."

9. Related Topics to Study Next

• PLI Scheme for Pharmaceuticals & Bulk Drugs — direct manufacturing complement.
• National Biopharma Mission (BIRAC, DBT) — precursor R&D mission.
• CDSCO & New Drugs and Clinical Trials Rules, 2019 — regulatory backbone.
• Jan Aushadhi (PMBJP) — affordability angle.
• BioE3 Policy (2024) — biomanufacturing/bioeconomy framework by DBT.
• TRIPS & compulsory licensing (Patents Act, 1970, §84) — biologics IP context.
• Ayushman Bharat — PM-JAY — demand-side for affordable biologics.
• Bulk Drug Parks scheme — API self-reliance link.

10. Common Errors / Trap Areas

• SHAKTI is under Department of Pharmaceuticals (Min. of Chemicals & Fertilizers) — NOT MoHFW, NOT DBT.
• Outlay is ₹10,000 cr / 5 years — do not confuse with the ₹13,000 cr figure (which bundles SHAKTI + 3 dedicated chemical parks) [S4].
• Clinical trial sites network sits under ICMR, not CDSCO; CDSCO gets a review cadre, not the trial sites.
• NIPER Act is 1998, not 1996; current NIPERs = 7 (Mohali is the first).
• SHAKTI ≠ National Biopharma Mission (2017, DBT-BIRAC, World Bank assisted) — different ministry, different vintage.

11. Sources

• [S1] BUDGET PUSH TO MAKE INDIA A GLOBAL BIOPHARMA HUB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221492 — (tier 1)
• [S2] Transforming India into a Global Biopharma Hub — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2222079 — (tier 1)
• [S3] Biopharma SHAKTI (Strategy…) Proposed in Union Budget 2026-27 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221443 — (tier 1)
• [S4] ₹13,000 cr for BioPharma SHAKTI & 3 Dedicated Chemical Parks — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2235160 — (tier 1)